Symbiox FY26 Net Profit at ₹15.23 Lakh, Revenue Declines

2 min read     Updated on 23 May 2026, 03:33 PM
scanx
Reviewed by
Suketu GScanX News Team
AI Summary

Symbiox Investment & Trading Co. Ltd. announced its audited financial results for the year ended March 31, 2026, revealing a decline in net profit to ₹15.23 lakh and revenue to ₹160.29 lakh. The company reported a net cash flow from operating activities of ₹272.59 lakh and total assets of ₹3,197.60 lakh. Additionally, the board re-appointed Mr. Akhil Agarwal as Secretarial Auditor and Mrs. Shikha Singhal Chartered Accountants as Internal Auditor for the upcoming financial year.

powered bylight_fuzz_icon
41075957

*this image is generated using AI for illustrative purposes only.

Symbiox Investment & Trading Co. Ltd. has released its audited financial results for the year ended March 31, 2026. The board of directors approved the results during a meeting held on May 23, 2026. The company reported a decline in both revenue and net profit for the fiscal year compared to the previous year.

Financial Performance

For the year ended March 31, 2026, the company recorded a net profit of ₹15.23 lakh, down from ₹19.19 lakh in the prior year. Revenue from operations decreased significantly to ₹160.29 lakh from ₹276.36 lakh in FY25. Total income for the period stood at ₹160.52 lakh.

The company's total expenses for the year were ₹139.94 lakh, lower than the ₹250.86 lakh reported in the previous year. Profit before tax for FY26 was ₹20.58 lakh, compared to ₹25.93 lakh in FY25. The basic earnings per share (EPS) for the year were reported at ₹0.049, down from ₹0.061 in the previous year.

Quarterly and Annual Results

The financial performance for the quarter ended March 31, 2026, showed a net profit of ₹1.22 lakh on a revenue of ₹82.73 lakh. In comparison, the quarter ended March 31, 2025, had reported a net loss of ₹29.94 lakh.

Particulars Year Ended 31-03-2026 (₹ in Lakh) Year Ended 31-03-2025 (₹ in Lakh)
Revenue From Operations 160.29 276.36
Total Income 160.52 276.79
Total Expenses 139.94 250.86
Profit Before Tax 20.58 25.93
Net Profit 15.23 19.19
Basic EPS 0.049 0.061

Balance Sheet and Cash Flow

As of March 31, 2026, the company's total assets were valued at ₹3,197.60 lakh, slightly higher than ₹3,196.59 lakh in the previous year. Total equity stood at ₹3,187.63 lakh, while total liabilities were reported at ₹9.97 lakh.

The cash flow statement for the year ended March 31, 2026, showed a net cash flow from operating activities of ₹272.59 lakh. Net cash used in investing activities was ₹261.29 lakh. Consequently, the net cash flow during the year was ₹11.30 lakh, bringing the closing cash and cash equivalents to ₹117.18 lakh.

Board Appointments

In addition to the financial results, the board approved the re-appointment of Mr. Akhil Agarwal, Practising Company Secretary, as the Secretarial Auditor for FY 2026-27. The board also re-appointed Mrs. Shikha Singhal Chartered Accountants as the Internal Auditor for the same financial year. The statutory auditors issued an unmodified opinion on the audited financial results.

Historical Stock Returns for Symbiox Investment & Trading

1 Day5 Days1 Month6 Months1 Year5 Years
-2.82%-4.44%-8.99%-41.69%-44.16%+100.00%

What strategic initiatives is Symbiox Investment & Trading planning to reverse the ~42% decline in revenue from operations in FY27?

How will the company deploy the ₹261.29 lakh invested in investing activities, and what returns are expected in the coming fiscal year?

Given the significant gap between total assets (₹3,197.60 lakh) and revenue (₹160.29 lakh), how effectively is Symbiox utilizing its asset base compared to industry peers?

Symbiox Investment & Trading
View Company Insights
View All News
like16
dislike

Symbiox Investment & Trading Co. Ltd. Schedules Board Meeting on May 23, 2026 to Approve Q4 and Full-Year FY26 Financial Results

1 min read     Updated on 14 May 2026, 05:55 PM
scanx
Reviewed by
Shriram SScanX News Team
AI Summary

Symbiox Investment & Trading Co. Ltd. has scheduled a Board of Directors meeting for May 23, 2026, at 1:30 P.M. at its registered office in Kolkata. The meeting, convened under Regulation 29 of SEBI (LODR) Regulations, 2015, will consider the approval of audited financial results for the quarter and year ended March 31, 2026. The board will also deliberate on the appointment of Mr. Akhil Agarwal as Secretarial Auditor and Mrs. Shikha Singhal as Internal Auditor for FY 2026-27. The notice was filed with the Metropolitan Stock Exchange, Calcutta Stock Exchange, and Bombay Stock Exchange on May 14, 2026.

powered bylight_fuzz_icon
40307120

*this image is generated using AI for illustrative purposes only.

Symbiox Investment & Trading Co. Ltd. has intimated stock exchanges of a forthcoming Board of Directors meeting, scheduled for Saturday, May 23, 2026, at 1:30 P.M. at the company's registered office in Kolkata. The notice, dated May 14, 2026, has been filed pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and has been communicated to the Metropolitan Stock Exchange of India Limited, The Calcutta Stock Exchange Limited, and The Bombay Stock Exchange Limited.

Board Meeting Agenda

The board meeting has been convened to transact several key matters. The following agenda items are scheduled for consideration:

Agenda Item: Details
Financial Results Approval: Audited Financial Results for the quarter and year ended March 31, 2026
Limited Review Report: Approval of Limited Review Report on Financial Results for the quarter and year ended March 31, 2026
Secretarial Auditor Appointment: Appointment of Mr. Akhil Agarwal, Practising Company Secretary, as Secretarial Auditor for FY 2026-27
Internal Auditor Appointment: Appointment of Mrs. Shikha Singhal, Chartered Accountant, as Internal Auditor for FY 2026-27
Other Business: Any other matter with the permission of the Chairperson

Key Regulatory Context

The approval of financial results will be carried out under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which governs the disclosure of financial results by listed entities. The board will consider both the audited financial results and the associated limited review report for the quarter and full year ended March 31, 2026.

Auditor Appointments for FY 2026-27

Among the notable agenda items are two auditor appointments for the upcoming financial year. The board will consider appointing Mr. Akhil Agarwal, Practising Company Secretary, as Secretarial Auditor of the company for FY 2026-27. Additionally, the appointment of Mrs. Shikha Singhal, Chartered Accountant, as Internal Auditor for FY 2026-27 will also be deliberated upon.

The intimation was signed by Khushboo Pitti, Company Secretary and Compliance Officer (M. No. A25950), on behalf of Symbiox Investment & Trading Co. Ltd.

Historical Stock Returns for Symbiox Investment & Trading

1 Day5 Days1 Month6 Months1 Year5 Years
-2.82%-4.44%-8.99%-41.69%-44.16%+100.00%

How might Symbiox Investment & Trading's audited financial results for FY 2026 compare to the previous year, and what trends could emerge in its investment and trading portfolio performance?

Could the appointment of new secretarial and internal auditors for FY 2026-27 signal any upcoming changes in Symbiox's corporate governance framework or compliance strategy?

What potential impact could the disclosed financial results have on Symbiox's stock performance across the three exchanges — BSE, CSE, and MSEI — particularly given its relatively niche listing profile?

Symbiox Investment & Trading
View Company Insights
View All News
like20
dislike

More News on Symbiox Investment & Trading

1 Year Returns:-44.16%